Multiple sclerosis (MS) has a longitudinal and heterogeneous course, with an increasing
number of therapy options and associated risk profiles, leading to a constant increase in the …

Multiple sclerosis (MS) as a chronic, degenerative autoimmune disease of the central
nervous system has a longitudinal and heterogeneous course with increasing treatment …

Multiple sclerosis (MS) is a highly heterogeneous disease as it can present inter-individually
as well as intra-individually, with different disease phenotypes emerging during different …

Background: Multiple sclerosis (MS) is a highly heterogeneous disease, both in its course
and in its response to treatments. Effective biomarkers may help predict disability …

The classification of multiple sclerosis (MS) has been established by Lublin in 1996 and
revised in 2013. The revision includes clinically isolated syndrome, relapsing-remitting …

A proper clinical evaluation of patients with Multiple Sclerosis (MS) is of great importance to
detect MS progression. It provides important data for physicians on their daily practice as …

Multiple sclerosis (MS) is a chronic progressive disease and many patients transition from
an initial relapsing–remitting course to a secondary progressive pattern. Accurate …

Background There is a growing need to offer persons with multiple sclerosis (PwMS)
possibilities for self-management and to integrate multidisciplinary health data. In 2009 …

The therapeutic approach in multiple sclerosis (MS) requires a personalized medicine frame
beyond the precision medicine concept, which is not currently implementable due to the lack …

Background: Multiple sclerosis (MS) is a progressive disease associated with a large variety
of symptoms and changing patients' needs during the disease course. In order to provide …